Gynecological Cancer Drugs Global Market Report 2024

The gynecological cancer drugs market size has grown strongly in recent years. It will grow from $13.87 billion in 2023 to $14.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The historical period's growth can be ascribed to the increasing advancements in chemotherapy, developments in hormone therapy, progress in early detection and diagnosis methods, innovations in surgical techniques, government funding and research grants, as well as the rise in awareness and screening programs.

The gynecological cancer drugs market size is expected to see strong growth in the next few years. It will grow to $19.01 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period is linked to factors such as the rising incidence rates of gynecological cancers, advancements in biomarker research, government funding and support, the increasing aging population, and progress in clinical trial methodologies. Notable trends expected in the forecast period involve initiatives focused on health equity and access, advancements in diagnostic tools, the exploration of combination therapies and targeted agents, the integration of telemedicine and remote monitoring, the adoption of patient-centric care models, and increased collaborations and partnerships.

The prevalence of gynecological cancer is poised to drive the growth of the gynecological cancer drugs market in the future. Gynecologic cancer encompasses cancers originating in a woman's reproductive organs, and drugs tailored for these conditions play a crucial role in reducing their prevalence. These drugs are instrumental in treating and managing gynecological cancer, preventing recurrence, and enhancing patient outcomes through diverse therapeutic approaches. For example, data from the World Ovarian Cancer Coalition in February 2022 indicated that ovarian cancer affected 313,959 women globally in 2020, and this number is projected to increase by 42% to 445,721 by 2040. Over the same period, there is an expected 51% rise in the number of women succumbing to ovarian cancer, from 207,252 to 313,617. Hence, the elevated prevalence of gynecological cancer is a key driver for the expansion of the gynecological cancer drugs market.

The growth of the gynecological cancer drug market is anticipated to be propelled by the increasing health awareness among consumers. Health awareness involves a comprehensive understanding of health, healthcare services, and health needs. In the context of gynecological cancer, heightened health awareness is critical for early detection and treatment, significantly improving outcomes. It encompasses initiatives to educate individuals about diseases, health risks, and the importance of prevention, empowering them to take control of their health. For instance, a report from Koninklijke DSM N.V. in August 2023 highlighted that in response to the pandemic, 60% of consumers worldwide are now more concerned about their health, placing a higher priority on leading healthy lives to avoid health problems. Therefore, the growing health awareness among consumers acts as a driving force for the expansion of the gynecological cancer drug market.

The adoption of advanced therapeutics emerges as a prominent trend in the gynecological cancer drugs market, with major companies introducing innovative treatment options to maintain their market standing. In December 2021, the UK government, in collaboration with the Scottish Medicines Consortium, introduced a groundbreaking combination for women diagnosed with ovarian cancer. This marks the inaugural availability of a combination therapy involving two ovarian cancer drugs, Olaparib (Lynparza) and bevacizumab (Avastin), for newly diagnosed women with advanced, high-grade serous ovarian cancer. The combination is specifically tailored for women whose tumors exhibit susceptibility to these drugs through HRD testing, a new genomic testing approach.

Key players in the gynecological cancer drug market are directing their focus toward personalized cancer vaccines to enhance customer offerings. Personalized cancer vaccines represent an emerging treatment approach that leverages a patient's own cancer cells to develop a vaccine aimed at instructing the immune system on how to recognize and eliminate the cancer. Pharmaceutical companies are integrating genetic sequencing and precision medicine to develop novel drug therapies and cancer treatments tailored to specific patients. For example, in January 2023, BioNTech, a Germany-based biotechnology company, announced plans to initiate trials for personalized cancer vaccines in the UK by September 2023. The company further aims to conduct tests and deliver 10,000 personalized mRNA therapies, including cancer vaccines, by the end of 2030.

In April 2021, Amgen Inc., a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics for $1.9 billion. This strategic move serves to expand, diversify, and strengthen Amgen's oncology portfolio by incorporating Five Prime Therapeutics' assets focused on immune-oncology and targeted cancer therapy drugs for various cancers, including lung, breast, and ovarian cancers.

Major companies operating in the gynecological cancer drugs market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, Fresenius Kabi AG, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Baxter International Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Ipsen, Dr Reddy’s Laboratories, Cipla Ltd., Apotex Inc., Hikma Pharmaceuticals, Seagen Inc., CSL Vifor, Accord Healthcare, Spectrum Pharmaceuticals Inc.

North America was the dominant region in the gynecological cancer drugs market in 2023. The regions covered in the gynecological cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gynecological cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of gynecological cancer drugs include alkylating agents, plant alkaloids, anthracyclines, antitumor antibiotics, and others. Alkylating agents, for instance, are a type of chemotherapy drug that disrupts the DNA of cancer cells, impeding their replication and inducing cell death. In gynecological cancer treatment, these drugs serve as cytotoxic treatments to target and eliminate cancer cells in reproductive organs such as the ovaries, uterus, cervix, and more. Various therapeutic modalities, including chemotherapy, targeted therapy, and hormonal therapy, are employed for different indications such as cervical cancer, uterine cancer, ovarian and fallopian tube cancer, vulvar cancer, and vaginal cancer. These treatments are administered in diverse healthcare settings, including hospitals, clinics, specialized cancer treatment centers, and other medical facilities.

The gynecological cancer drugs market research report is one of a series of new reports that provides gynecological cancer drugs market statistics, including gynecological cancer drugs industry global market size, regional shares, competitors with a gynecological cancer drugs market share, detailed gynecological cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecological cancer drugs industry. This gynecological cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecological cancer drugs market consists of revenues earned by entities by providing immunotherapy, anti-angiogenesis, and radiation therapy. The market value includes the values of related goods sold by the service provider or included within the service offering. The gynecological cancer drugs market also includes sales of platinum-based chemotherapy drugs, taxane-based chemotherapy drugs, PARP inhibitors, and angiogenesis inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.